Comparative Pharmacology
Head-to-head clinical analysis: IMODIUM A D EZ CHEWS versus LOMOTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMODIUM A D EZ CHEWS versus LOMOTIL.
IMODIUM A-D EZ CHEWS vs LOMOTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loperamide is a synthetic piperidine derivative that acts directly on intestinal muscle to slow peristalsis, thereby reducing stool frequency and increasing stool consistency. It binds to μ-opioid receptors in the myenteric plexus of the gastrointestinal tract, decreasing acetylcholine release and inhibiting peristalsis. It has minimal central nervous system activity due to poor bioavailability and efflux by P-glycoprotein.
Diphenoxylate is a meperidine congener that acts as an opioid receptor agonist, inhibiting gastrointestinal motility and prolonging transit time; atropine is added to discourage abuse at high doses.
4 mg orally initially, then 2 mg after each unformed stool; maximum 8 mg/day for OTC use (prescription: up to 16 mg/day).
Adults: 2 tablets (2.5 mg diphenoxylate/0.025 mg atropine) orally four times daily until control of diarrhea is achieved; maintenance dose is 2 tablets once or twice daily. Maximum dose: 8 tablets (20 mg diphenoxylate) per day.
None Documented
None Documented
Terminal elimination half-life is approximately 9–14 hours (mean ~10.8 hours) in healthy adults. In patients with hepatic impairment, half-life may be prolonged.
Diphenoxylate: 2.5-3.5 hours; Difenoxin (active metabolite): 12-24 hours. Clinically, antidiarrheal effect is prolonged due to metabolite accumulation.
Primarily hepatic metabolism with biliary excretion of metabolites; ~1% renal excretion of unchanged drug. Fecal elimination accounts for ~90% of the dose, mainly as conjugated metabolites, with ~1% as unchanged loperamide.
Primarily renal (50-70% as metabolites, <5% unchanged) and fecal (30-50% via biliary excretion).
Category C
Category C
Antidiarrheal
Antidiarrheal